Skip to main content

Drug Interactions between digoxin and Rythmol

This report displays the potential drug interactions for the following 2 drugs:

Edit list (add/remove drugs)

Interactions between your drugs

Major

digoxin propafenone

Applies to: digoxin and Rythmol (propafenone)

ADJUST DOSE: Coadministration with propafenone may increase the exposure and toxicity of digoxin. The proposed mechanism is increased absorption and/or reduced clearance of digoxin due to inhibition of the P-glycoprotein (P-gp) efflux transporter (present in the intestine, liver, and kidney) by propafenone and two of its major metabolites. Concomitant use of propafenone and digoxin has been reported to increase the systemic exposure (AUC) of digoxin in patients by 29% to 270%, depending on the dose of propafenone and dosage form of digoxin. One clinical trial reported serum digoxin levels increased by about 35% when combined with propafenone 450 mg/day and by about 85% when combined with propafenone 900 mg/day, indicating that propafenone's effects are dose related. The magnitude of change in digoxin exposure has generally been found to be lower when digoxin is administered intravenously as opposed to orally.

MANAGEMENT: If concomitant use of digoxin and propafenone is clinically necessary, some manufacturers recommend either a reduction in digoxin's dose, or a modification in digoxin's dosing frequency, accompanied by additional monitoring for signs and symptoms of toxicity. For example, reducing digoxin's dose by approximately 15% to 30% for the injectable formulation or 30% to 50% for the oral formulation if propafenone is initiated in a patient on digoxin is recommended by some manufacturers of digoxin. Serum digoxin concentrations should be measured before initiation and patients should be closely monitored for and counseled on signs of toxicity. Additional drug level monitoring and dose adjustment may be required. Consultation with digoxin's product labeling for more specific guidance may be advisable.

References (14)
  1. Belz GG, Doering W, Munkes R, Matthews J (1983) "Interaction between digoxin and calcium antagonists and antiarrhythmic drugs." Clin Pharmacol Ther, 33, p. 410-7
  2. Calvo MV, Martin-Suarez A, Luengo CM, et al. (1989) "Interaction between digoxin and propafenone." Ther Drug Monit, 11, p. 10-5
  3. Nolan PE Jr, Marcus FI, Erstad BL, Hoyer GL, Furman C, Kirsten EB (1989) "Effects of coadministration of propafenone on the pharmacokinetics of digoxin in healthy volunteer subjects." J Clin Pharmacol, 29, p. 46-52
  4. Bigot MC, Debruyne D, Bonnefoy L, Grollier G, Moulin M, Potier JC (1991) "Serum digoxin levels related to plasma propafenone levels during concomitant treatment." J Clin Pharmacol, 31, p. 521-6
  5. Calvo MV, Martin-Suarez A, Luengo CM, Avila C, Cascon M, Dominguez-Gil Hurle A (1989) "Interaction between digoxin and propafenone." Ther Drug Monit, 11, p. 10-5
  6. Zalzstein E, Koren G, Bryson SM, Freedom RM (1990) "Interaction between digoxin and propafenone in children." J Pediatr, 116, p. 310-2
  7. (2022) "Product Information. PMS-Digoxin (digoxin)." Pharmascience Inc
  8. (2023) "Product Information. Apo-Propafenone (propafenone)." Apotex Incorporated
  9. (2022) "Product Information. Propafenone (propafenone)." Accord-UK Ltd
  10. (2025) "Product Information. Digoxin (digoxin)." Hikma Pharmaceuticals USA Inc.
  11. (2025) "Product Information. Lanoxin (digoxin)." Covis Pharmaceuticals
  12. (2024) "Product Information. Digoxin (digoxin)." Amneal Pharmaceuticals LLC
  13. (2025) "Product Information. Digoxin (digoxin)." Aurobindo Pharma USA Inc
  14. (2018) "Product Information. Rythmol (propafenone)." GlaxoSmithKline

Drug and food/lifestyle interactions

Moderate

propafenone food/lifestyle

Applies to: Rythmol (propafenone)

GENERALLY AVOID: Grapefruit juice may increase the plasma concentrations of propafenone. The proposed mechanism is inhibition of CYP450 3A4-mediated first-pass metabolism in the gut wall by certain compounds present in grapefruit. Inhibition of hepatic CYP450 3A4 may also contribute. In over 90% of patients, propafenone is rapidly and extensively converted to 2 active metabolites: 5-hydroxypropafenone via CYP450 2D6 and N-depropylpropafenone (norpropafenone) via CYP450 3A4 and 1A2. In less than 10% of patients (approximately 6% of Caucasians in the U.S. population), however, metabolism of propafenone is slower because the 5-hydroxy metabolite is not formed, or minimally formed, due to a genetic deficiency in CYP450 2D6. In these poor metabolizers of CYP450 2D6, clearance of propafenone via the CYP450 3A4 and 1A2 metabolic pathways becomes more important, and inhibition of these pathways may substantially increase systemic exposure to propafenone. Likewise, patients taking concomitant inhibitors of CYP450 2D6 and 3A4 may experience similar pharmacokinetic effects. In general, the effect of grapefruit juice is concentration-, dose- and preparation-dependent, and can vary widely among brands. Certain preparations of grapefruit juice (e.g., high dose, double strength) have sometimes demonstrated potent inhibition of CYP450 3A4, while other preparations (e.g., low dose, single strength) have typically demonstrated moderate inhibition. Increased systemic exposure to propafenone may result in proarrhythmic events and exaggerated beta-adrenergic blocking activity.

MANAGEMENT: It may be advisable for patients to avoid the consumption of grapefruit, grapefruit juice, or supplements that contain grapefruit during treatment with propafenone.

References (4)
  1. Botsch S, Gautier JC, Beaune P, Eichelbaum M, Kroemer HK (1993) "Identification and characterization of the cytochrome P450 enzymes involved in N-dealkylation of propafenone: molecular base for interaction potential and variable disposition of active metabolites." Mol Pharmacol, 43, p. 120-6
  2. (2011) "Product Information. Rythmol SR (propafenone)." GlaxoSmithKline
  3. (2023) "Product Information. Apo-Propafenone (propafenone)." Apotex Incorporated
  4. (2022) "Product Information. Propafenone (propafenone)." Accord-UK Ltd
Minor

digoxin food/lifestyle

Applies to: digoxin

Administration of digoxin with a high-fiber meal has been shown to decrease its bioavailability by almost 20%. Fiber can sequester up to 45% of the drug when given orally. Patients should be advised to maintain a regular diet without significant fluctuation in fiber intake while digoxin is being titrated.

Grapefruit juice may modestly increase the plasma concentrations of digoxin. The mechanism is increased absorption of digoxin due to mild inhibition of intestinal P-glycoprotein by certain compounds present in grapefruits. In 12 healthy volunteers, administration of grapefruit juice with and 30 minutes before, as well as 3.5, 7.5, and 11.5 hours after a single digoxin dose (0.5 mg) increased the mean area under the plasma concentration-time curve (AUC) of digoxin by just 9% compared to administration with water. Moreover, P-glycoprotein genetic polymorphism does not appear to influence the magnitude of the effects of grapefruit juice on digoxin. Thus, the interaction is unlikely to be of clinical significance.

References (2)
  1. Darcy PF (1995) "Nutrient-drug interactions." Adverse Drug React Toxicol Rev, 14, p. 233-54
  2. Becquemont L, Verstuyft C, Kerb R, et al. (2001) "Effect of grapefruit juice on digoxin pharmacokinetics in humans." Clin Pharmacol Ther, 70, p. 311-6

Therapeutic duplication warnings

Therapeutic duplication is the use of more than one medicine from the same drug category or therapeutic class to treat the same condition. This can be intentional in cases where drugs with similar actions are used together for demonstrated therapeutic benefit. It can also be unintentional in cases where a patient has been treated by more than one doctor, or had prescriptions filled at more than one pharmacy, and can have potentially adverse consequences.

Duplication

Antiarrhythmics

Therapeutic duplication

The recommended maximum number of medicines in the 'antiarrhythmics' category to be taken concurrently is usually one. Your list includes two medicines belonging to the 'antiarrhythmics' category:

  • digoxin
  • Rythmol (propafenone)

Note: In certain circumstances, the benefits of taking this combination of drugs may outweigh any risks. Always consult your healthcare provider before making changes to your medications or dosage.


Drug Interaction Classification

These classifications are only a guideline. The relevance of a particular drug interaction to a specific individual is difficult to determine. Always consult your healthcare provider before starting or stopping any medication.
Major Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit.
Moderate Moderately clinically significant. Usually avoid combinations; use it only under special circumstances.
Minor Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan.
Unknown No interaction information available.

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.